Evidence map›Paper›PMID 33433884›Full record

ReviewEndocrine pathology2021

Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites.

Silvia Uccella, Stefano La Rosa, Jasna Metovic, Deborah Marchiori, Jean-Yves Scoazec, Marco Volante, Ozgur Mete, Mauro Papotti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Pancreatic neuroendocrine tumors: A case-based evidence review.World journal of gastrointestinal pathophysiology · 2025
    Review
  16. Metabolic changes in neuroendocrine neoplasms.Cellular and molecular life sciences : CMLS · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Silvia UccellaPathology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy. silvia.uccella@uninsubria.it.ORCID http://orcid.org/0000-0002-5714-7295
Stefano La RosaInstitute of Pathology, University Hospital and University of Lausanne, Lausanne, Switzerland.
Jasna MetovicDepartment of Oncology, University of Turin, Torino, Italy.
Deborah MarchioriPathology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Jean-Yves ScoazecDepartment of Pathology, Gustave Roussy Cancer Campus, Paris, France.
Marco VolanteDepartment of Oncology, University of Turin, Torino, Italy.
Ozgur MeteDepartment of Pathology, University Health Network, Toronto, ON, Canada.
Mauro PapottiDepartment of Oncology, University of Turin, Torino, Italy.
University of Turin · ITUniversity of Insubria · ITInstitut Gustave Roussy · FRUniversity Health Network · CAUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade neuroendocrine neoplasms (HG-NENs) are clinically aggressive diseases, the classification of which has recently been redefined. They now include both poorly differentiated NENs (neuroendocrine carcinoma, NECs) and high proliferating well-differentiated NENs (called grade 3 neuroendocrine tumors, G3 NETs, in the digestive system). In the last decade, the "molecular revolution" that has affected all fields of medical oncology has also shed light in the understanding of HG NENs heterogeneity and has provided new diagnostic and therapeutic tools, useful in the management of these malignancies. Considering the kaleidoscopic aspects of HG NENs in various anatomical sites, this review systematically addresses the genomic landscape of such neoplasm throughout the more common thoracic and digestive locations, as well as it will consider other rare but not exceptional primary sites, including the skin, the head and neck, and the urogenital system. The revision of the available literature will then be oriented to understand the translational relevance of molecular data, by analyzing conceptual issues, clinicopathological correlations, and unmet needs in this field.

Indexed as

GenomicsCarcinoma, NeuroendocrineHumansNeoplasm GradingNeuroendocrine TumorsPathology, MolecularGeneticsGenomicsGrade 3 neuroendocrine tumorHigh-grade neuroendocrine neoplasmsMolecular analysisNeuroendocrine carcinoma

Identifiers

PMID33433884
OpenAlexW3119682527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.